Targanta Therapeutics Announces Positive Top-Line Results From Oritavancin Phase 2 SIMPLIFI Trial - Antibiotic Targeting Gram-positive Organisms

�Targanta Therapeutics Corporation (Nasdaq: TARG) announced positive top-line results from a Phase 2 clinical trial investigating the efficacy and safety of oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI. Oritavancin is Targanta's lead antibiotic prospect targeting gram-positive organisms, including methicillin-resistant Staphylococcus aureus, or MRSA. Oritavancin, administered in a single or in an infrequent dosing regime, demonstrated like efficacy and safety to a three-to-seven day line of oritavancin therapy, as administered in two antecedently conducted Phase 3 clinical trials for the treatment of cSSSI. Each of these Phase 3 clinical trials met their primary endpoint.


These top-line efficacy results from SIMPLIFI ar consistent with Targanta's antecedently published preclinical studies. The SIMPLIFI trial run was intentional based on oritavancin's unique pharmacokinetic profile and demonstrated concentration-dependent bactericidal activity.


Mark Leuchtenberger, President and CEO of Targanta, commented, "We believe the potential to cure cSSSI with simply a single or infrequent dosing regimen could make oritavancin the go-to drug of pick among physicians who ar seeking an effective and convenient weapon for their antibiotic armamentarium, and thereby lead to a dislodge in the treatment image for gram-positive infections. With the SIMPLIFI results in hand, we will set about to purpose a bigger confirmatory tribulation that could demonstrate oritavancin's potential as the market's first good single or infrequent endovenous (IV) treatment of cSSSI caused by gram-positive bacterium."


Results of the Phase 2 SIMPLIFI trial volition be victimized to designing a Phase 3 written report to appraise the benefits and risks of a single-dose regime for the treatment of cSSSI. Targanta expects full data from SIMPLIFI volition be presented prior to the final stage of the year.

About SIMPLIFI


The Phase 2 SIMPLIFI test was an international, multi-center, randomized, double blind, controlled subject area of some 300 patients with cSSSI, including MRSA. SIMPLIFI measured clinical response to oritavancin (either cure or improvement versus bankruptcy) at the first followup visit (Test of Cure) in clinically evaluable patients as its primary terminus. The survey examined the safety of oritavancin in all intent-to-treat patients as its junior-grade endpoint.


Additional details around the SIMPLIFI trial design can be found in a press release dated May 20, 2008, "Targanta Completes Enrollment in Phase 2 Oritavancin Infrequent Dosing Study," set up on the Investor Relations section of Targanta's site at world Wide Web.targanta.com/investors/newsrelease.html.

About Oritavancin


Oritavancin is a novel man-made lipoglycopeptide antibiotic drug candidate with potent bactericidal (killing) activity against a broad spectrum of gram-positive bacteria. In its intravenous (IV) formulation, the production candidate has been tried and true in over 2,four hundred individuals and has realised two Phase 3 studies for the treatment of complicated skin and skin structure infections (cSSSI) in which the primary endpoints were met. Targanta submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in February 2008 seeking to commercialize oritavancin for the treatment of cSSSI; the FDA recognised the NDA submission for standard review, establishing an action day of the month of December 8, 2008. Targanta's Marketing Authorization Application (MAA) for oritavancin was accepted for review by the European Medicines Agency (EMEA) in June 2008. Targanta is also development an oral version of oritavancin for the possible treatment of Clostridium difficile-related conditions.

About Targanta Therapeutics


Targanta Therapeutics Corporation (Nasdaq: TARG) is a biopharmaceutical company focussed on development and commercializing innovative antibiotics to do by serious infections in the hospital and other institutional settings. The Company's word of mouth includes an intravenous version of oritavancin, a semisynthetic lipoglycopeptide antibiotic currently awaiting U.S. and EU regulatory approval, and, a computer programme to develop an oral version of oritavancin for the handling of Clostridium difficile. The Company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Qu�bec, Canada. For more than information on Targanta, visit http://www.targanta.com.

Safe Harbor Statement


This press outlet contains "forward-looking statements" that are made pursuant to the safe harbor viands of the Private Securities Litigation Reform Act of 1995. These are statements that ar predictive in nature, that depend upon or refer to future events or conditions or that include words such as "potential," "may," "will," "expects," "projects," "anticipates," "estimates," "believes," "intends," "plans," "should," "seeks," "hope" and alike expressions. Such statements include, but are not limited to the potential to cure cSSSI with exactly a undivided or infrequent dosing regimen of oritavancin; oritavancin seemly the antibiotic drug of choice among physicians; and oritavancin's potency as the market's number one effective, single or infrequent intravenous (IV) infusion for treatment of cSSSI caused by gram-positive bacteria. Forward-looking statements involve known and unknown risks and uncertainties that crataegus oxycantha cause literal future results to differ materially from those sticking or contemplated in the forward-looking statements. Forward-looking statements may be significantly wedged by certain risks and uncertainties described in Targanta's filings with the Securities and Exchange Commission. The risks and uncertainties referred to higher up include, just are not limited to, delays in obtaining or a failure to obtain regulatory blessing for Targanta's product candidates; unfavorable clinical trial results; Targanta's potentiality inability to initiate and complete presymptomatic studies and clinical trials for its product candidates; the possibility that results of preclinical studies are not necessarily predictive of clinical trial results; and those other risk factors that are described more fully in the Company's filings with the Securities and Exchange Commission. Targanta does non undertake any obligation to update whatsoever of these forward-looking statements to reverberate a variety in its views or events or circumstances that occur after the date of this release.

Targanta Therapeutics


More information

• Great Lake monster on camera?
• Confusion Surrounds Simplicity Bassinet Recall
• CDC Declares End to Salmonella Outbreak
• Air travel is a headache for flyers
• Why flies are so hard to swat

Pamela Anderson dating a royal - report - New Zealandhttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'s source for entertainment news, gossip & music, motion-picture show & book reviews on Stuff.co.nz



Event.observe(window, http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'loadhttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/', function() {
check_comment_order();
show_top_comments();
});




Stuff

Trade Me
Travelbug
Find Someone
Old Friends
Smaps
RugbyHeaven

Make Stuff.co.nz my homepage




Entertainment Headlines

� Eva Longoriahttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'s baby desperation

� Eastwood motion-picture photography All Black movie

� Madonna turns 50 (+photos, television)

� Review: Our Street in Auckland

� Katie dips toe into fashion innovation

� William Shatner signs off on young video autographs

� Siennahttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'s momma defends daughterhttp://www.material.co.nz/http://www.material.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff and nonsense.co.nz/'s relationship

� Batman star escapes charges in family row

� DMX arrested after missing court date

� Harry Potter fans side eight calendar month delay

� Rachel Hunterhttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'s fight confirmed

� Country Clendar, Outrageous fortune come funding

� Ihttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'m not pretty, Penelope Cruz says

� Hugh Hefnerhttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'s Playboy parties banned
Entertainment feature







Pop icon Madonna turns 50
�Story, photos, videos, discography, links and more







Sponsored Links


































Opinion Poll

Is an extra octonary months excessively long to wait for the succeeding Harry Potter film, Harry Potter and the Half-Blood Prince?
See story

Yes - I was looking forward to a November release


No - Ithttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'s excessively late to do anything about it


Doesnhttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'t worry me either way

Entertainment quiz







Test your entertainment knowledge
�Click here to start quiz





Sponsored Links















Photo gallery







Tom, Katie rock the Tropic Thunder premiere
�Latest showbiz pics





Blog







Chris Schulzhttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'s entertainment blog
� Best links of the week





Features







Sowing the seeds of success









Cutting those Apron Strings





Most commented on







Angelina Jolie seeks Catwoman tips from porno star









End bad motion-picture show sequels, says mag





On the box







Top 10 TV picks: August 12-18









The best films on the box: August 12-18









Jane Bowron: Shaddap you face, DCI Hunthttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'s back





Gossip






What the Kiwi gossip mags say: August 12









Film reappraisal: Star Wars: The Clone Wars









What the Kiwi gossip mags say: August 5





Latest reviews







Film review: Wanted









CD review: Solid Ground - The Black Seeds





Competitions







Win Robot Chicken: Star Wars on DVD









Win a copy of 10,000 BC on DVD









Win a copy of 100% Blues on CD





Contact details







Contact us







Editorshttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/' Picks

� Eastwood filming All Black movie

� Sonny Bill disengage from Bulldogs for $750k

� Clinical Cantabs give Auks six of the best

� Warriors keep up imperativeness for playoffs spot

� http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/'Bigfoothttp://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/http://www.stuff.co.nz/' fails DNA test

� Canadians get homegrown porn channel

� Pupils let hemp go to their heads



�




Gossip
|
Film
|
Music
|
TV
|
Books
|
Arts
|
Fashion
|
Games
|
Photos
|
Videos
|
Competitions
|
Blog: The Hit List
|
Blog: Beats Me
|
Blog: About Town
|
Blog: Reeling
|
Blog: Blog on the Tracks
|
Blog: Game Junkie
|
Blog: Page Turner
Home
|
News
|
Sport
|
Business
|
Entertainment
|
Lifestyle
|
Travel
|
Tech
|
Newspapers
|
Magazines


Site Map
|
About Stuff
|
Feedback
|
Advertise Online With Us
|
Place a Newspaper Classified Ad
|
A to Z directories
|
Magazine Subscriptions
|
Competitions
|
RSS



� Fairfax New Zealand Limited 2007. All the material on this thomas Nelson Page has the protection of international right of first publication. All rights reserved.
























_uacct = "UA-1056754-1";
urchinTracker();

/* */
var _rsCI="nz-stuff";
var _rsCG="s-stuff-entertainment-ttstorytt-4657305-ttsourcett-bangshowbiz";
var _rsDN="//secure-nz.imrworldwide.com/";
var _rsSE=1;
var _rsSM=0.1;
var _rsCL=1;
/* */

Saturday, 9 August 2008

Jolie agrees deal for photos of twins

Angelina Jolie and Brad Pitt have agreed a multi-million euro deal for the first photos of their twins, Knox and Vivienne.

The deal is with Hello! cartridge holder and the issue volition be on sale on Monday 4 August.

The Press Association quotes an unidentified magazine source as locution: "This is one of the publishing sensations of the decade - Brad and Angelina are the dream duo of the glossy cartridge clip world and we anticipate to triple our circulation because of the public's fascination and interest in the duo and their children."

More information

• Lil Wayne Predictably Sued by Litigious Geezers
• Kate Nash sings joins Mystery Jets on new song
• Cultivate
• Riley Lee and Colin Wilson
• New German film to shed light on Hitler’s trial

Sinner

   
Artist: Sinner

   Genre(s): 
Metal
   Metal: Heavy
   

---

Discography:


   
 Mask Of Sanity

   Year: 2007   
Tracks: 12


   
 There Will Be Execution

   Year: 2003   
Tracks: 12


   
 The End Of Sanctuary

   Year: 2000   
Tracks: 12


   
 The Second Decade

   Year: 1999   
Tracks: 15


   
 The Nature Of Evil

   Year: 1998   
Tracks: 13


   
 Judgement Day

   Year: 1997   
Tracks: 11


   
 Comin' Out Fighting

   Year: 1986   
Tracks: 10


   
 Danger Zone

   Year: 1984   
Tracks: 11


   
 Fast Decision

   Year: 1983   
Tracks: 10


   
 Wild'n'evil

   Year: 1982   
Tracks: 11

---

Led by vocalist Mats Sinner, Sinner was a German metal ring reminiscent of countrymen like the Scorpions and Accept. Their first American spill, Fast Decision, appeared in 1983; it was followed a year later by Danger Zone, widely considered their deuce best records. Several more albums followed in front the band called it quits in 1988; later on Sinner and guitar player Tom Naumann played together with Helloween's Kai Hansen in a dance band called Primal Fear, which released a self-titled debut in 1998, the erstwhile deuce resurrected Sinner for a new album. Dubbed The Nature of Evil, the disk was released later that year. The End of Sanctuary followed in 2000.

West Wing star joins Desperate Housewives

After a lengthy search, the actor who will play Katherine Mayfair's (Dana Delany) ex-husband in 'Desperate Housewives' has been found.
TV Guide reports that former 'West Wing' star Gary Cole has signed on to play the character.
Cole's first episode will be screened on US TV on 20 April.
The actor's other credits include 'Midnight Caller' and 'Office Space'.
For more on 'Desperate Housewives', read our blog here.

Reality TV rejects set for Eurovision?

A number of former reality television stars are set to compete for the chance to represent the UK at this year's Eurovision Song Contest.
Among those vying for the chance to perform at the event in Belgrade in May are former 'X Factor' star Andy Abraham, 'Any Dream Will Do' star Rob McVeigh and 'How Do You Solve a Problem Like Maria?' contestant Simona Armstrong.
They will face competition from former 'EastEnders' star Michelle Gayle, pop duo Loveshy (made up of contestants from 'Popstars: The Rivals') and girl group The Revelations.
The six acts will take part in the 'Eurovision - Your Decision' programme next month, with the winner becoming the UK's official entry for the Eurovision.
BBC's Eurovision host Terry Wogan said: "A turkey is one of the contenders for this year's Irish entry. For the past few years, we've been picking a turkey for the UK.
"Let's hope that the British public will make the right decision this year and give the UK's entry a fighting chance against the Eastern Bloc in Belgrade in May."
For more on Ireland's Eurovision hopefuls, click here.

El Chicano recaptures the magic at the Greek

On Sunday at the Greek Theatre, a reunited El Chicano showed that the band is worthy of renewed attention as one of the most accomplished exponents of the Eastside sound. Led by the white-haired Bobby Espinosa -- who was perched behind his beloved Hammond B-3 organ, draped for the occasion in a colorful Mexican serape -- El Chicano performed on the second of a two-night concert series called Latin Legends Live!, now in its seventh year at the Greek.

The weekend lineup included other warhorses of the Chicano nostalgia circuit, including headliners War and Tierra, along with Thee Midniters and Malo with Jorge Santana.

Tierra's lively party set featured brothers Rudy and Steve Salas, who once played with El Chicano and who had their own big reunion at the Conga Room in 2002. The band's outstanding current vocalist, Billy Mondragon, could have won the night's "Chicano Idol" competition for his soulfulness, power and pure falsettos.




Sunday's afternoon gloom might have slightly dampened the turnout. But the audience of mostly middle-aged Mexican Americans, many with the trademark goatees and tattoos of veteranos, filled the amphitheater with celebratory enthusiasm for the old-school music that served as a soundtrack for their youth.

The night offered a welcome reminder of how many excellent musicians emerged from the California Chicano community after the success of Carlos Santana and his trademark pop concoction, Latin rock. Unfortunately, nostalgia now fills a void because Chicano bands, with the exception of Los Lobos, have struggled to recapture the 1970s level of popularity.

While not strictly a Chicano band, War (Eric Burden's ex-backup group) fits the Santana mold with its multicultural makeup and its fusion of rock, R&B, salsa and jazz, exemplified by its 1975 Top 10 hit "Low Rider."

El Chicano's "Viva Tirado" was one of those pop music flukes, a jazzy instrumental written by pianist Gerald Wilson, an African American who happened to love bullfighting. El Chicano's 1970 cover version became a Top 40 hit, though it was recorded when the group was still known as the V.I.P.s, a moniker changed by a producer after signing a record deal. Overnight and unwittingly, the band was turned into a symbol for the tumultuous political movement that also called itself Chicano.

Espinosa has kept the group going with various lineups, but this is the first time in more than 20 years that almost all the early members were back on stage together. They include Freddie Sanchez (bass), Jerry Salas (vocals and guitar), Rudy Regalado (timbales), John De Luna (drums) and Mickey Lespron (guitar).

The band's veteran lead singer Ersi Arvizu was warmly received for a guest vocal on her signature bolero, "Sabor A Mi." She did the number like a diva and exited with a pitch: "Don't forget to buy my CD. Believe me, it sounds just like El Chicano." Well, not exactly. The work has little to do with Latin rock and stays truer to the bolero's romantic essence.

Lespron is the only band member who plays on Arvizu's album, "Friend for Life." On Sunday, he lit up the stage with thrilling guitar solos, switching to a vintage 1962 Gibson for "Viva Tirado," the guitar he used on the original recording.

"It felt great, man," said Lespron backstage after the show. "The magic's still there."

agustin.gurza@latimes.com